Document Detail

Attenuation and immunogenicity of Deltacya Deltacrp derivatives of Salmonella choleraesuis in pigs.
MedLine Citation:
PMID:  10456909     Owner:  NLM     Status:  MEDLINE    
Six different isogenic Deltacya Deltacrp derivatives of a strain of Salmonella choleraesuis var. kunzendorf-chi3246 virulent for pigs were constructed by transposon-mediated deletion mutagenesis. These strains were evaluated for virulence and ability to elicit a protective immune response in young weaned pigs after oral administration and were compared to a commercially available vaccine which lacks the 50-kb virulence plasmid (vpl(-)). These derivatives were Deltacya Deltacrp vpl(+), Deltacya Deltacrp vpl(-), Deltacya Delta(crp-cdt) vpl(+), Deltacya Delta(crp-cdt) vpl(-), Deltacya Deltacrp pmi-3834 vpl(+), and Deltacya Delta(crp-cdt) pmi-3834. In experiments to evaluate safety, no significant adverse effects of any of the vaccine constructs were observed, except that two of the strains which carried the virulence plasmid (vpl(+)) caused a small, short-term elevation in maximum temperature compared to pretreatment temperature values. Orally immunized animals, except for those vaccinated with the Deltacya Deltacrp pmi-3834 vpl(+) strain or SC-54, developed significant serum antibody responses 21 days postvaccination as measured by enzyme-linked immunosorbent assay. No cell-mediated immune responses to heat-killed S. choleraesuis were noted at the same time point as measured with heat-killed bacteria as antigen in a lymphocyte proliferation assay. In an oral challenge exposure model with a highly virulent heterologous strain of S. choleraesuis, the Deltacya Deltacrp strains with deletions in pmi were not protective. As measured by morbidity scores, the responses to challenge of the pigs vaccinated with the other four Deltacya Deltacrp derivatives were significantly better than those of the nonvaccinated, challenged group. With the exception of temperature elevation and slight differences in diarrhea scores postchallenge, none of these strains differed significantly from each other in the other clinical parameters analyzed. While the commercial vaccine was protective by most of the parameters measured, it was not fully protective against challenge with virulent S. choleraesuis as judged by diarrhea scores and temperature elevation. Collectively, these data demonstrate that Deltacya Deltacrp derivatives, with or without the virulence plasmid but not with deletions in the pmi gene, are candidates for vaccines for protection against salmonellosis in pigs.
M J Kennedy; R J Yancey; M S Sanchez; R A Rzepkowski; S M Kelly; R Curtiss
Related Documents :
24168129 - Economic evaluations of hepatitis a vaccination in middle-income countries.
8492099 - The jeryl lynn vaccine strain of mumps virus is a mixture of two distinct isolates.
23722879 - Molecular biology and inhibitors of hepatitis a virus.
925379 - Evaluation of a udp-glucose-4-epimeraseless mutant of salmonella typhi as a liver oral ...
7832699 - Development and evaluation of a non-isotopically labeled dna probe for the diagnosis of...
23637039 - Increased serum microrna-155 level associated with non-responsiveness to hepatitis b va...
6863909 - A comparison of live and inactivated influenza a (h1n1) virus vaccines. 1. short-term i...
24168129 - Economic evaluations of hepatitis a vaccination in middle-income countries.
25444819 - Natural killer t cell and tlr9 agonists as mucosal adjuvants for sublingual vaccination...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Infection and immunity     Volume:  67     ISSN:  0019-9567     ISO Abbreviation:  Infect. Immun.     Publication Date:  1999 Sep 
Date Detail:
Created Date:  1999-10-05     Completed Date:  1999-10-05     Revised Date:  2013-06-11    
Medline Journal Info:
Nlm Unique ID:  0246127     Medline TA:  Infect Immun     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  4628-36     Citation Subset:  IM    
Animal Health Discovery Research, Veterinary Infectious Diseases Section, Pharmacia & Upjohn, Inc., Kalamazoo, Michigan 49001, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibodies, Bacterial / blood,  immunology
Bacterial Vaccines / genetics,  immunology*
Carrier Proteins
Cyclic AMP / genetics
Cyclic AMP Receptor Protein / genetics*
Salmonella / genetics,  immunology*
Salmonella Infections / immunology,  microbiology,  pathology,  prevention & control
Vaccines, Attenuated
Reg. No./Substance:
0/Antibodies, Bacterial; 0/Bacterial Vaccines; 0/Carrier Proteins; 0/Cyclic AMP Receptor Protein; 0/Vaccines, Attenuated; 60-92-4/Cyclic AMP

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The capsule of Cryptococcus neoformans reduces T-lymphocyte proliferation by reducing phagocytosis, ...
Next Document:  Characterization of VspB of Borrelia turicatae, a major outer membrane protein expressed in blood an...